Implementation of a weight loss program for latino outpatients with severe mental illness

Community Mental Health Journal

Volumn 49, Issue 2, 2013, Pages 150-156

  Mangurian, Christina ^a,b,c   Chaudhry, Simriti ^a,b   Capitelli, Lucia ^a   Amiel, Jonathan ^a,b   Rosario, Felicia ^b   Jackson, Carlos ^a,b   Newcomer, John W ^d   Cournos, Francine ^a,b   Essock, Susan ^a,b   Barrett, Diane ^a,b   Devlin, Michael ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Howard Hughes Medical Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Latino; Metabolic syndrome; Obesity; Severe mental illness; Weight loss program

Indexed keywords

AGED; ARTICLE; BEHAVIOR THERAPY; ETHNOLOGY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH PROMOTION; HISPANIC; HUMAN; MALE; MENTAL DISEASE; METHODOLOGY; MIDDLE AGED; OBESITY; OUTPATIENT; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STATISTICS; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

AGED; BEHAVIOR THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH PROMOTION; HISPANIC AMERICANS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NEW YORK; OUTPATIENTS; OVERWEIGHT; PATIENT EDUCATION AS TOPIC; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; WEIGHT LOSS; WEIGHT REDUCTION PROGRAMS;

EID: 84877919775     PISSN: 00103853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10597-012-9506-1     Document Type: Article

References (41)

1. Alegria, M., Chatterji, P., Wells, K., Cao, Z., Chen, C. N., Takeuchi, D., et al. (2008). Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatric Services, 59(11), 1264-1272.
2. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156(11), 1686-1696.
3. Allison, D. B., Newcomer, J. W., Dunn, A. L., Blumenthal, J. A., Fabricatore, A. N., Daumit, G. L., et al. (2009). Obesity among those with mental disorders: a National Institute of Mental Health meeting report. American Journal of Preventive Medicine, 36(4), 341-350.
4. Amiel, J. M., Mangurian, C. V., Ganguli, R., & Newcomer, J. W. (2008). Addressing cardiometabolic risk during treatment with antipsychotic medications. Current Opinion in Psychiatry, 21(6), 613-618.
5. Attkisson, C. C., & Zwick, R. (1982). The Client Satisfaction Questionnaire: Psychometric properties and correlations with service utilization and psychotherapy outcome. Evaluation and Program Planning, 5(3), 233-237.
6. Baptista, T., Kin, N. M., Beaulieu, S., & de Baptista, E. A. (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry, 35(6), 205-219.
7. Brar, J. S., Ganguli, R., Pandina, G., Turkoz, I., Berry, S., & Mahmoud, R. (2005). Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry, 66(2), 205-212.
8. Cabassa, L. J., Ezell, J. M., & Lewis-Fernandez, R. (2010). Lifestyle interventions for adults with serious mental illness: a systematic literature review. Psychiatric Services, 61(8), 774-782.
9. Casey, D. E. (2005). Metabolic issues and cardiovascular disease in patients with psychiatric disorders. The American Journal of Medicine, 118(Suppl 2), 15S-22S.
10. Colton, C. W., & Manderscheid, R. W (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3, A42, Retrieved 1/6/2011, from http://www.cdc.gov/pcd/issues/2006/apr/05-0180.htm.
11. Daumit, G. L., Clark, J. M., Steinwachs, D. M., Graham, C. M., Lehman, A., & Ford, D. E. (2003). Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. The Journal of Nervous and Mental Disease, 191(12), 799-805.
12. Davidson, S., Judd, F., Jolley, D., Hocking, B., Thompson, S., & Hyland, B. (2001). Cardiovascular risk factors for people with mental illness. The Australian and New Zealand Journal of Psychiatry, 35(2), 196-202.
13. Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., & Goldberg, R. W. (2010). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 48-70.
14. Essock, S. M., Covell, N. H., Leckman-Westin, E., Lieberman, J. A., Sederer, L. I., Kealey, E., et al. (2009). Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York State. Psychiatric Services, 60(12), 1595-1602.
15. Gilmer, T. P., Ojeda, V. D., Barrio, C., Fuentes, D., Garcia, P., Lanouette, N. M., & Lee, K. C. (2009). Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency. Psychiatric Services (Washington D.C.), 60(2), 175-182.
16. Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry, 166(3), 345-353.
17. Hellerstein, D. J., Almeida, G., Devlin, M. J., Mendelsohn, N., Helfand, S., Dragatsi, D., et al. (2007). Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting. Psychiatric Quarterly, 78(3), 171-181.
18. Kalarchian, M. A., Marcus, M. D., Levine, M. D., Haas, G. L., Greeno, C. G., Weissfeld, L. A., et al. (2005). Behavioral treatment of obesity in patients taking antipsychotic medications. The Journal of Clinical Psychiatry, 66(8), 1058-1063.
19. Kato, M. M., Currier, M. B., Gomez, C. M., Hail, L., & Gonzalez-Blanco, M. (2004). Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients with Schizophrenia. Primary Care Companion to the Journal of Clinical Psychiatry, 6(2), 74-77.
20. Kraemer, H. C. (2005). A simple effect size indicator for two-group comparisons? A comment on r equivalent. Psychological Methods, 10(4), 413-419.
21. Lambert, T. J., Velakoulis, D., & Pantelis, C. (2003). Medical comorbidity in schizophrenia. The Medical Journal of Australia, 178(Suppl), S67-s70.
22. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209-1223.
23. Mangurian, C., Goss, E., & Newcomer, J. W. (2010). Metabolic Screening, Prevalence, and Treatment Preferences in Predominantly Hispanic Severely Mentally Ill Inpatients. Psychiatric Services, 61, 1162-1163.
24. Mangurian, C., Stowe, M., & Devlin, M. J. (2009). Obesity treatment for urban, low-income Latinos with severe mental illness. Psychiatric Services, 60(8), 1139.
25. Mangurian, C., Stowe, M., Violante, J., & Devlinet, M. (2007). Health Eating and Activity in Latinos Treated in the Heights (HEALTH) Course Manual (English). From http://www.columbia.edu/~fc15/ index-files/PDFs/Manual-En.pdf.
26. Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., et al. (2004). Physical health monitoring of patients with schizophrenia. The American Journal of Psychiatry, 161(8), 1334-1349.
27. McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80(1), 19-32.
28. Mier, N., Ory, M. G., & Medina, A. A. (2009). Anatomy of Culturally Sensitive Interventions Promoting Nutrition and Exercise in Hispanics: A Critical Examination of Existing Literature. Health Promotion Practice, 11(4), 541-554.
29. Morrato, E. H., Newcomer, J. W., Allen, R. R., & Valuck, R. J. (2008). Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. The Journal of Clinical Psychiatry, 69(2), 316-322.
30. Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86(1-3), 15-22.
31. National Institute of Health. (2001). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). The Journal of the American Medical Association, 28, 2486-2497.
32. Newcomer, J. W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(Suppl 1), 1-93.
33. Newcomer, J. W., Campos, J. A., Marcus, R. N., Breder, C., Berman, R. M., Kerselaers, W., et al. (2008). A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of Clinical Psychiatry, 69(7), 1046-1056.
34. Newcomer, J. W., & Hennekens, C. H. (2007). Severe mental illness and risk of cardiovascular disease. The Journal of the American Medical Association, 298(15), 1794-1796.
35. Park, Y. W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003). The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of Internal Medicine, 163(4), 427-436.
36. th technical report. Retrieved 1/6/2011, from http://www.nasmhpd.org/general-files/publications/med- directors-pubs/ NASMHPD%20Medical%20Directors%20Health%20Indicators%20Report%2011-19-08.pdf.
37. Roberts, R. E., & Attkisson, C. C. (1983). Assessing client satisfaction among Hispanics. Evaluation and Program Planning, 6(3-4), 401-413.
38. Smedley, B. D., Stith, A. Y., & Nelson, A. R. (2003). Unequal treatment: Confronting racial and ethnic disparities in health care. Washington, DC: The National Academy Press.
39. Ware, J., Jr, Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220-233.
40. Weiden, P. J. (2007). Understanding and addressing adherence issues in schizophrenia: from theory to practice. The Journal of Clinical Psychiatry, 68(Suppl 14), 14-19.
41. Weiden, P. J., Newcomer, J. W., Loebel, A. D., Yang, R., & Lebovitz, H. E. (2008). Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology, 33(5), 985-994.